Assertio (NASDAQ:ASRT – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.
Assertio Stock Down 9.0 %
Shares of Assertio stock traded down $0.11 on Tuesday, hitting $1.11. The company had a trading volume of 1,343,982 shares, compared to its average volume of 1,044,132. Assertio has a twelve month low of $0.73 and a twelve month high of $8.01. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.83 and a quick ratio of 1.43. The stock has a 50-day moving average of $0.94 and a 200-day moving average of $1.08. The firm has a market capitalization of $105.58 million, a P/E ratio of -0.28 and a beta of 1.00.
Assertio (NASDAQ:ASRT – Get Free Report) last released its earnings results on Monday, March 11th. The company reported $0.08 earnings per share (EPS) for the quarter. Assertio had a positive return on equity of 6.30% and a negative net margin of 218.28%. The firm had revenue of $32.99 million during the quarter, compared to analysts’ expectations of $31.42 million. Research analysts predict that Assertio will post -0.04 earnings per share for the current year.
Institutional Investors Weigh In On Assertio
About Assertio
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
See Also
- Five stocks we like better than Assertio
- Canadian Penny Stocks: Can They Make You Rich?
- Garmin Navigates to New Highs Driven By Wearables Trend
- Consumer Discretionary Stocks Explained
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.